Kiromic BioPharma, Inc.
KRBP
Price:
$2.03
Market Cap:
$3.14M
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement ...[Read more]
Industry
Biotechnology
IPO Date
2020-10-16
Stock Exchange
NASDAQ
Ticker
KRBP
The PE Ratio as of September 2024 (TTM) for Kiromic BioPharma, Inc. (KRBP) is -0.32
According to Kiromic BioPharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.32. This represents a change of 276.95% compared to the average of -0.08 of the last 4 quarters.
Kiromic BioPharma, Inc. (KRBP) Historical PE Ratio (quarterly & annually)
How has KRBP PE Ratio performed in the past?
The mean historical PE Ratio of Kiromic BioPharma, Inc. over the last ten years is -4.22. The current -0.32 PE Ratio has changed 657.86% with respect to the historical average. Over the past ten years (40 quarters), KRBP's PE Ratio was at its highest in in the June 2001 quarter at 0. The PE Ratio was at its lowest in in the June 2019 quarter at -39.78.
Average
-4.22
Median
-1.33
Minimum
-11.90
Maximum
-0.04
Kiromic BioPharma, Inc. (KRBP) PE Ratio by Quarter and Year
Discovering the peaks and valleys of Kiromic BioPharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 11.73%
Maximum Annual PE Ratio = -0.04
Minimum Annual Increase = -88.65%
Minimum Annual PE Ratio = -11.90
| Year | PE Ratio | Change |
|---|---|---|
| 2023 | -0.04 | -41.99% |
| 2022 | -0.08 | -88.65% |
| 2021 | -0.68 | -65.74% |
| 2020 | -1.99 | -83.29% |
| 2019 | -11.90 | 11.73% |
Kiromic BioPharma, Inc. (KRBP) Average PE Ratio
How has KRBP PE Ratio performed in the past?
The current PE Ratio of Kiromic BioPharma, Inc. (KRBP) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-0.27
5-year avg
-2.94
10-year avg
-4.22
Kiromic BioPharma, Inc. (KRBP) PE Ratio vs. Peers
How is KRBP’s PE Ratio compared to its peers?
Kiromic BioPharma, Inc.’s PE Ratio is greater than Quoin Pharmaceuticals, Ltd. (-0.47), less than Allarity Therapeutics, Inc. (-0.19), greater than Virax Biolabs Group Limited (-1.34), less than Biodexa Pharmaceuticals Plc (-0.05), greater than Zura Bio Limited (-9.00), less than Altamira Therapeutics Ltd. (-0.03), greater than Immix Biopharma, Inc. (-2.98), greater than Enveric Biosciences, Inc. (-0.36), less than Palisade Bio, Inc. (-0.31), less than CNS Pharmaceuticals, Inc. (-0.00), less than eFFECTOR Therapeutics, Inc. (-0.00), less than Navidea Biopharmaceuticals, Inc. (0.03), greater than Sonnet BioTherapeutics Holdings, Inc. (-0.55), greater than Sigilon Therapeutics, Inc. (-1.90), greater than Reviva Pharmaceuticals Holdings, Inc. (-1.10), less than ZyVersa Therapeutics, Inc. (-0.10), greater than Unicycive Therapeutics, Inc. (-0.46),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.47 | $3.06M | |
| -0.19 | $7.01M | |
| -1.34 | $15.24M | |
| -0.05 | $105.64K | |
| -9.00 | $230.86M | |
| -0.03 | $2.04M | |
| -2.98 | $54.08M | |
| -0.36 | $4.53M | |
| -0.31 | $4.25M | |
| -0.00 | $4.60M | |
| -0.00 | $188.18K | |
| 0.03 | $100.08K | |
| -0.55 | $4.53M | |
| -1.90 | $56.22M | |
| -1.10 | $44.68M | |
| -0.10 | $2.70M | |
| -0.46 | $33.41M |
Build a custom stock screener for Kiromic BioPharma, Inc. (KRBP) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kiromic BioPharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Kiromic BioPharma, Inc. (KRBP) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Kiromic BioPharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the PE Ratio?
How can you use the PE Ratio?
What is Kiromic BioPharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for Kiromic BioPharma, Inc. (KRBP)?
What is the highest PE Ratio for Kiromic BioPharma, Inc. (KRBP)?
What is the 3-year average PE Ratio for Kiromic BioPharma, Inc. (KRBP)?
What is the 5-year average PE Ratio for Kiromic BioPharma, Inc. (KRBP)?
How does the current PE Ratio for Kiromic BioPharma, Inc. (KRBP) compare to its historical average?